March of Dimes Responds To Ther-Rx
White Plains, New York | Friday, April 1, 2011
Media ContactsMichele Kling (914-997-4613)
Ther-Rx Corporation’s decision to reduce the list price of Makena to $690 and to expand patient financial assistance are steps in the right direction toward making an FDA-approved progesterone therapy product more widely available. Nevertheless, the March of Dimes has decided to exercise our right to terminate our current contract and sever all professional relationships with Ther-Rx. The company's handling of the launch of Makena, and the initial list price, were highly unsatisfactory and unacceptable to the March of Dimes and the families we represent. The March of Dimes will continue to explore all options for ensuring access to progesterone therapy for all medically eligible women. Access for women to treatment to prevent premature birth is and always has been our paramount concern. We hope that the controversy surrounding Makena has helped raise awareness that progesterone therapy is a safe and effective treatment for prevention of preterm birth and that more obstetricians will consider it for appropriate patients.
About March of Dimes
March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every baby can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we empower every mom and every family.